Introduction
CJC-1295 No DAC (also known as Mod GRF 1-29) and CJC-1295 with DAC are both synthetic analogs of growth hormone-releasing hormone (GHRH), but the addition of the Drug Affinity Complex (DAC) fundamentally alters their pharmacokinetic profiles. This distinction is critical for researchers studying growth hormone physiology, as it determines whether GH release mimics natural pulsatile secretion or produces sustained elevation.
Mechanism of Action Comparison
Both peptides bind the GHRH receptor on anterior pituitary somatotroph cells, activating adenylyl cyclase and cAMP-dependent pathways that stimulate growth hormone synthesis and release. CJC-1295 No DAC has a half-life of approximately 30 minutes, producing sharp GH pulses that closely mimic the body's natural pulsatile secretion pattern. It is typically administered 2-3 times daily to generate multiple physiological GH peaks.
CJC-1295 with DAC incorporates a maleimidopropionic acid linker that binds covalently to albumin in circulation. This albumin conjugation extends the half-life to 6-8 days, creating sustained GH elevation rather than discrete pulses. A single injection produces measurably elevated GH and IGF-1 levels for up to two weeks[1].
Key Differences
| Feature | CJC-1295 No DAC | CJC-1295 with DAC |
|---|---|---|
| Half-life | ~30 minutes | ~6-8 days |
| GH Release Pattern | Pulsatile (physiological) | Sustained elevation |
| Dosing Frequency | 2-3x daily (or with secretagogue) | 1-2x per week |
| IGF-1 Elevation | Transient peaks | Sustained elevation for days |
| GH Desensitization Risk | Low (mimics natural pattern) | Higher (continuous stimulation) |
| Common Pairing | Ipamorelin, GHRP-6, GHRP-2 | Used alone or with secretagogues |
Research Applications
CJC-1295 No DAC is preferred for studies requiring physiological GH pulsatility, anti-aging protocols, and combination research with GH secretagogues like Ipamorelin or GHRP-6. The pulsatile release pattern reduces somatotroph desensitization and more closely models endogenous GH secretion. CJC-1295 with DAC is suited for studies requiring sustained IGF-1 elevation, simplified dosing protocols, or investigation of prolonged GHRH receptor activation effects.
Which to Choose for Your Research?
For physiological GH studies, anti-aging research, or protocols combining GHRH with secretagogues, CJC-1295 No DAC is generally preferred due to its pulsatile release pattern and lower desensitization risk. For convenience-focused protocols or studies specifically examining sustained GH/IGF-1 elevation, CJC-1295 with DAC offers a simpler dosing regimen. Most growth hormone optimization research favors the No DAC variant paired with Ipamorelin for synergistic pulsatile GH release.
